Reconstituted Peptide Stability: How Long Vials Actually Last at 4°C
The shelf-life numbers printed on a peptide vial describe the lyophilised powder before reconstitution, sealed and stored at the manufacturer’s recommended temperature, and they have very little to do with the working stability of the same compound once a user adds bacteriostatic water and starts drawing daily doses from the vial in their own refrigerator. The working stability window is shorter than the publication half-life for predictable reasons, and a protocol that treats the two numbers as the same one ends up running a cycle on a vial that is meaningfully less potent at the end than at the start. The framework below covers what actually changes in the vial across days and weeks at 4°C, why the published stability data is the upper bound rather than the working number, and the log fields that make the degradation curve visible across a cycle.
What reconstitution starts
The lyophilised peptide is a dry crystalline powder, and the reconstitution event is the point at which the molecule moves from the dry state, where the dominant degradation pathway is oxidation of any exposed residues on a timescale of months to years, into the aqueous state, where the dominant degradation pathways are hydrolysis of the amide bonds, deamidation of the asparagine and glutamine side chains, and oxidation of the methionine, tryptophan, and cysteine residues, all on a timescale of days to weeks. The bacteriostatic water itself is not the source of the degradation; the water is the medium in which the molecule is now mobile, exposed, and reactive. The benzyl alcohol in the bacteriostatic preparation suppresses microbial growth but does not stop the molecular degradation, and a vial that is sterile after four weeks is not necessarily a vial that is at full potency after four weeks.
The temperature exponent
Stability data for the major peptides is typically reported at three temperatures: room temperature around 25°C, refrigerator temperature at 4°C, and freezer temperature at –20°C. The degradation rate roughly doubles for every 10°C of temperature increase across the relevant range, which means a vial at 4°C degrades roughly four times slower than the same vial at 25°C, and a vial at –20°C degrades roughly four times slower again than the 4°C reference. The practical consequence is that the refrigerator buys an order of magnitude of stability over the kitchen counter, the freezer buys another order of magnitude over the refrigerator, and a vial that sits out at room temperature for an hour twice a day during the dosing window loses meaningful potency that the cumulative refrigerator hours do not recover. Our storage primer covers the practical temperature management; the timeline below is the consequence of the chemistry, not a separate variable.
The week-by-week working timeline at 4°C
The first week after reconstitution is the cleanest part of the stability curve for nearly every peptide in the consumer protocols. The molecule is at its formulated concentration, the degradation products are at trace levels, and a daily draw from the vial is reading the same compound as the day before. The second week is still inside the working window for most peptides, with the cumulative loss in the low single-digit percentage range for compounds with stable backbones and somewhat higher for compounds with exposed methionine or tryptophan residues. The third and fourth weeks are where the protocols diverge. A GLP-1 agonist with a stabilised backbone such as semaglutide remains within a working potency range for the full four to six week pen interval the formulation was designed around, while a short-chain peptide such as ipamorelin or a flexible-fold compound such as BPC-157 has measurably lost activity by the end of week three and is on the edge of the working window by the end of week four. The clinical-grade stability data published for each class supports a different working window, and the user-facing rule of thumb that says all peptides last four weeks in the fridge is the average of two distributions that are not the same.
What the cumulative draw events do
A vial is not just sitting at 4°C for the duration of the cycle; it is being removed from the refrigerator, warmed in the hand or on the counter for the draw, exposed to the room air for the seconds the needle is inserted, and returned to the refrigerator. A daily protocol does this seven times a week, a twice-daily protocol fourteen times, and the cumulative time-at-warm and air-exposure is a real input to the degradation curve that the static stability data does not capture. The practical effect is that a vial drawn from once daily for thirty days has roughly thirty cumulative warm exposures and thirty needle-insertion events, and a vial drawn from twice daily has sixty of each. The recommended practice in the lab literature is to minimise the time out of refrigeration, to draw the dose at the start of the warming window rather than the end, and to return the vial promptly. The recommendation in the consumer literature is the same, but the protocols that read this advice and act on it are a smaller fraction than the protocols that do not.
The aliquoting alternative
An aliquot is a sub-divided portion of the reconstituted peptide, transferred from the parent vial into a smaller container, and frozen at –20°C until the working window of the parent vial would otherwise be exceeded. The aliquoting practice extends the effective stability of a multi-week cycle by keeping the bulk of the compound at freezer temperature for the duration of the cycle and only thawing the portion that fits inside a working window. The cost is one extra freeze-thaw cycle per aliquot, which itself contributes to the degradation curve for some peptides through ice-crystal formation and pH shift on freezing. The published guidance for the GLP-1 class generally advises against freezing the reconstituted product because the freeze-thaw stress on the formulation is non-trivial, while the published guidance for the smaller bioregulator peptides such as the GHK-Cu, the thymosin family, and the BPC-157 class is more permissive of a single freeze-thaw cycle as long as it is documented in the log. The aliquoting decision is therefore peptide-specific and should be made before the reconstitution, not after.
The visible signs and what they mean
A reconstituted peptide that has lost stability does not necessarily change colour or develop visible particulates; the early degradation is invisible at the bench, and the user-facing rule that a clear solution is a good solution is only true in the very late stage of the degradation curve when the molecule has aggregated to the point of becoming optically detectable. The visible signs that do appear include a faint cloudiness from microbial growth in a vial whose bacteriostatic protection has been compromised, a colour change from clear to pale yellow in some compounds undergoing oxidation, and a slight froth or film at the stopper that suggests the molecule has begun to denature at the air-water interface. None of these are specific markers of stability loss, and the absence of all three does not confirm that the vial is at full potency. The reliable input to the stability question is the date of reconstitution, the storage temperature, the temperature exposures during draws, and the published stability data for the specific compound, not the optical inspection of the vial.
The log fields that make this readable
A cycle log that records the reconstitution date, the bacteriostatic-water volume, the resulting concentration, the storage location, and the count of draw events per day is the structure that lets a later read attribute a marker movement to the dose, the compound, or the degradation curve rather than to an undifferentiated mixture of the three. The reconstitution date is the start of the working window. The volume and concentration are the read of the dose against the labelled potency; our reconstitution math covers the calculation. The storage location captures whether the vial has been in the refrigerator throughout or has spent time out for travel or work, and the draw-event count captures the cumulative warm-exposure burden. Together these five fields make the degradation a logged variable rather than a hidden one, and a cycle that ends with no benefit on the marker has a structured way of asking whether the cause was the dose, the compound, or the stability of the working stock.
What this is not
None of the above is medical advice or a sourcing recommendation. The framework describes the chemical and procedural variables that make a working-stock decision readable inside a self-managed protocol, not the clinical decision to run that protocol at all. Peptides include prescription and non-prescription compounds in jurisdictions where the regulatory status varies, and the reconstitution, storage, and dosing decisions belong to the user and a qualified clinician. Peptra does not source peptides, does not endorse vendors, and does not provide compound-specific clinical guidance for any individual.
The practical summary
A reconstituted peptide vial at 4°C has a working stability window that is shorter than the publication half-life and that depends on the backbone of the specific compound, the count and duration of the daily warm exposures, and the cumulative needle-insertion events across the cycle. The first two weeks are clean for nearly every compound in the consumer protocols, the third and fourth weeks split the protocols by compound class, and the aliquoting practice is the standard extension for cycles whose duration would otherwise exceed the working window of the parent vial. The reconstitution date, the concentration, the storage location, and the draw-event count are the four fields a log needs to keep the stability curve visible across the cycle, and the working assumption is that the published shelf life is the upper bound, not the working number.